Diverse alterations associated with resistance to KRAS(G12C) inhibition.

doi:10.1038/s41586-021-04065-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Diverse alterations associated with resistance to KRAS(G12C) inhibition.

Nature - 1 Nov 2021

Zhao Yulei, Murciano-Goroff Yonina R, Xue Jenny Y, Ang Agnes, Lucas Jessica, Mai Trang T, Da Cruz Paula Arnaud F, Saiki Anne Y, Mohn Deanna, Achanta Pragathi, Sisk Ann E, Arora Kanika S, Roy Rohan S, Kim Dongsung, Li Chuanchuan, Lim Lee P, Li Mark, Bahr Amber, Loomis Brian R, de Stanchina Elisa, Reis-Filho Jorge S, Weigelt Britta, Berger Michael, Riely Gregory, Arbour Kathryn C, Lipford J Russell, Li Bob T, Lito Piro

Abstract excerpt

Inactive state-selective KRAS(G12C) inhibitors1-8 demonstrate a 30-40% response rate and result in approximately 6-month median progression-free survival in patients with lung cancer9. The genetic basis for resistance to these first-in-class mutant GTPase inhibitors remains under investigation. Here we evaluated matched pre-treatment and post-treatment specimens from 43 patients treated with the KRAS(G12C)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to MAP Kinase Signaling System

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 34759319
DOI: 10.1038/s41586-021-04065-2
PMCID: PMC8887821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diverse alterations associated with resistance to KRAS(G12C) inhibition.PMID 34759319Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancerSemantic proximity Read ↗

RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.Semantic proximity Read ↗

The promise and peril of KRAS G12C inhibitors.Semantic proximity Read ↗

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.Semantic proximity Read ↗

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.Semantic proximity Read ↗

From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.